ASAH1 and lysosomal storage disease: However, FIASMAs, at least in vitro, lack specificity and were shown to inhibit other important lysosomal hydrolases due to the indirect mechanism of action, like acid ceramidase (AC) (19, 20), lysosomal acid lipase (21), and phospholipases A and C, leading to phospholipidosis (22–25).